New Approach for Protection of Chickens against Mycoplasma Gallisepticum and Avian Influenza H9 Disease Using a Nano-Oil Adjuvanted Combined Inactivated Vaccine

Author(s)

Mahmoud. M. Abotaleb , Fatma M. Gad , Fatma El Zahraa Gamal , Rasha G. Tawfik , Manar F. Seioudy , Hala A.Shaheen , Reem A. Soliman , Selim S. Salama ,

Download Full PDF Pages: 35-43 | Views: 28 | Downloads: 9 | DOI: 10.5281/zenodo.15585814

Volume 9 - April 2025 (04)

Abstract

Mycoplasma gallisepticum is the main agent of chronic respiratory disease and also it helps greatly co-infection with low pathogenic avian Influenza (H9N2) in chickens. The protective efficacy of a combined inactivated vaccine, formulated with a locally prepared low-pathogenic avian influenza (LPAI) subtype H9N2 and Mycoplasma gallisepticum (MG), was evaluated in specific pathogen-free (SPF) chickens using nasal and subcutaneous routes. The prepared combined vaccine exhibited no adverse local or systemic reactions and was free from bacterial or fungal contamination. The immune response to LPAI H9N2 and MG was assessed using the hemagglutination inhibition (HI) and enzyme-linked immunosorbent assay (ELISA) tests.  The results demonstrated that the vaccine induced a high level of seroconversion via routes, beginning after the 2nd WPV and reaching peak at the 4th and 5th WPV. Antibody titers in chickens vaccinated via the subcutaneous (SC) route showed a stronger immune response compared to those vaccinated via the intranasal (IN) route. The mean reduction of viral shedding titers of LPAI H9N2 was done in SPF Embryonated chicken eggs (ECE) and it was found that 2.35 and 2 log₁₀ EID₅₀, using SC and IN routes respectively. Additionally, the challenged chicken groups against virulent MG strain after 4th WPV exhibited satisfactory protection, with protection rates of 90% and 80% for both routes, respectively. In conclusion, immunization with the inactivated combined vaccine adjuvanted with Montanide™ IMS 1313 N VG PR induced early and strong seroconversion, providing satisfactory protection compared to the control group. Adaptive immunity elicited via the SC route resulted in a higher immune response and stronger protection compared to the mucosal immunity induced via the IN route. The prepared vaccine is considered a promising vaccine when used to achieve protection against both MG and H9N2.

Keywords

Low Pathogenic Avian Influenza (H9N2), Mycoplasma gallisepticum, Inactivated combined vaccine, Nano-oil emulsion.

References

Xiaopan Liu , Hailong Hong , Jing Wang , Junjie Huang , Jiawen Li , Ya Tao , Mingjiang Liu , Huan Pang , Jingui Li , Ruonan Bo.  Mucosal immune responses and protective efficacy elicited by oral administration AMP-ZnONPs-adjuvanted inactivated H9N2 virus in chickens.  Poult Sci . 2024 Jan 26;103(4):103496. doi: 10.1016/j.psj.2024.103496

Ali ZM, Hassan MAEM, Hussein HA, Ahmed BM, Sanousi AAEE. Protective efficacy of combined trivalent inactivated ISA 71 oil adjuvant vaccine against avian influenza virus subtypes (H9N2 and H5N1) and Newcastle disease virus. Vet World. 2017;10(10):1212-20. doi: https://10.14202/vetworld.2017.1212-1220.


Singh , S.M., Alkie,T.N., Hodgins,D.C., Nagi, E’., Shojadoost, P. and Sharif, S. et al., (2015): Systemic immune responses to an inactivated, whole H9N2 avian influenza virus vaccine using class B CPG oligonucleotides in chickens. Vaccine 33, 3947-3952.

WOAH 2024, Manual of Diagnostic Tests and Vaccines for Terrestrial Animals, twelfth edition, Chapter 3.3.4, Avian influenza (including infection with high pathogenicity avian influenza viruses) and Chapter 3.3.5, Avian mycoplasmosis (Mycoplasma gallisepticum, M. synoviae). 

Atalla H, Lysnyansky I, Raviv Y, Rottem S. Mycoplasma gallisepticum inactivated by targeting the hydrophobic   domain of the membrane preserves surface lipoproteins and induces a strong immune response. PloS One. 2015;10(3):e0120462.

Bekele L, Assefa T. Inactivated vaccine trial of Mycoplasma gallisepticum in Ethiopia. Open J Vet Med. 2018;8(6):75-85.

Noor Mounira, Shamsul M, Basit M, Ahmed S, Muhammad D,Rajib M, et al. Evaluation of the Immunogenicity of Oil-Based Mycoplasma gallisepticum Killed Vaccine in Broiler Chickens Experimentally Prepared from Local Isolate of Bangladesh. J Anim Vet Adv. 2020;19(8).

Dhakal, S. and Renukaradhya, G.J. Nanoparticlebased vaccine development and evaluation against viral infections in pigs. Vet. Res. 2019; 50, 90.

Jang, S.I., Lillehoj, H.S., Lee, S.H., Lee, K.W., Lillehoj, E.P., Bertrand, F., Dupuis, L. and Deville, S. Montanide IMS 1313 N VG PR nanoparticle adjuvant enhances antigen-specific immune responses to profilin following mucosal vaccination against Eimeria acervulina. Vet. Parasitol. 2011; 182(2–4), 163–170.

Matrosovich, M.N., Krauss, S., Webster, R.G., 2001. H9N2 influenza A vi-ruses from poultry in Asia have human virus-like receptor speci-ficity. Virology 281, 156–162.

El-Zoghby, E.F., Arafa, A.S., Hassan, M.K., Aly, M.M., Selim, A., Kilany, W.H., Selim, U., Nasef, S., Aggor, M.G., Abdelwhab, E.M., Hafez, H.M., 2012. Isolation of H9N2 avian influenza virus from bobwhite quail (Colinus virginianus) in Egypt. Archives of Virology 157, 1167–1172.

Abido O, Abotaleb MM, Nahed Y, Ayman HE, Aziza MA, Ahmed AE. Protective efficacy of an inactivated vaccine against rabbit hemorrhagic disease virus 2 prepared from a local isolate in Egypt. VacciMonitor 2020; 29 (3):143-150.

Abotaleb MM, Tawfik RG, Omar DM, Mohamed FH, Ali SM, Khalaf NM, Nassif SA. Evaluation of a prepared combined inactivated vaccine against hemorrhagic diseas virus 2 and Colstridium perfringens type A infections in rabbit. VacciMonitor 2024;33:e063324.

Abotaleb MM,Attia HM, Elsafty MM, Ali AM. Efficacy of Two Commercial Inactivated H5 Avian Influenza Vaccines against Circulating HPAI Subtype H5N8 in Quails,2018. Alixandria Jornal of Veterinary Sciences 2019;  AJVS. Vol. 59 (2): 11-16.

Gomaa MR, Khalil AA, Kandeil A,, Sabir JSM, Kayed A,  Moatasim Y, El saied MF, El-safty MM,  Kayali G, Ali MA.Development of an effective contemporary trivalent avian influenza vaccine against circulating H5N1, H5N8, and H9N2 in Egypt. Poultry Science 2019; 98:6289–6295.

El-Naggar MS, Ibrahim HM, Salem HM, Marouf S. A novel locally prepared inactivated bivalent Mycoplasma vaccine for chicken flocks in Egypt. Adv Anim Vet Sci. 2022; 10 (1):55-61.

Adams A. Progress, challenges and opportunities in fish vaccine development. Fish Shellfish Immunol. 2019; 90:210-214.

Rodwell AW, Whitcomb RF. Methods for direct and indirect measurement of Mycoplasma growth. Academic Press. 1983; 185-196

Cite this Article: